Broadfin Capital Initiates New Positions In Corium International Inc (CORI), AMAG Pharmaceuticals Inc. (AMAG) and La Jolla Pharmaceutical Company (LJPC)

In three recent filings,  Kevin Kotler’s Broadfin Capital has revealed adding three companies: Corium International Inc (NASDAQ:CORI), AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and La Jolla Pharmaceutical Company (NASDAQ:LJPCto its equity portfolio.

Kevin Kotler

A new filing with the Securities and Exchange Commission showed that Broadfin Capital currently owns 1.35 million shares of Corium International Inc (NASDAQ:CORI), representing 7.66% of common stock outstanding.

Corium International Inc (NASDAQ:CORI) is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products. Earlier in March, the company filed a registration statement on Form S-1 with for a proposed initial public offering of its common stock and later it priced its IPO of 6.50 million shares of common stock at a price to the public of $8.00 per share. The underwriters have been granted a 30-day option to purchase up to 975,000 additional shares of common stock at the IPO price.

In AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Broadfin Capital owns 1.43 million shares, the stake amasses 6.55% of the common stock. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the United States.

Last month, Jacob Gottlieb’s Visium Asset Management disclosed initiating a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG). Adage Capital Management, managed by Phill Gross and Robert Atchinson, held 3.80 million shares of the company at the end of 2013.

In another filing, Broadfin Capital disclosed owning a 5.37% passive stake in La Jolla Pharmaceutical Company (NASDAQ:LJPC). The new position contains around 389,900 common stock shares. La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.

Earlier this month, the fund revealed a reduced stake in MELA Sciences, Inc (NASDAQ:MELA), owning a total of 9.1 million shares, equal to almost 10% of the common stock, down from over 16% held earlier.

Disclosure: none

Recommended Reading:

Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)

Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!